Blurred boundaries: The therapeutics and politics of medical marijuana

Mayo Clinic Proceedings

Volumn 87, Issue 2, 2012, Pages 172-186

  Bostwick, J Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID RECEPTOR AGONIST; CANNABIS; DRONABINOL; NABILONE; NABIXIMOLS; RIMONABANT;

ANOREXIA; ASTHMA; CANCER PAIN; CANNABIS ADDICTION; CANNABIS SMOKING; COGNITIVE CLOUDING; CONVULSION; COUGHING; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG LEGISLATION; DRUG MECHANISM; DYSPHORIA; EUPHORIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; LEGAL ASPECT; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PAIN; PRESCRIPTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SPASTICITY; TOBACCO DEPENDENCE; UNITED STATES; VOMITING; WASTING SYNDROME;

EID: 84856680285     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2011.10.003     Document Type: Review

References (112)

1. Carlini EA. The good and the bad effects of (-) trans-delta-9- tetrahydrocannabinol (Δ9-THC) on humans. Toxicon. 2004;44(4):461-467. (Pubitemid 39070645)
2. Annas GJ. Reefer madness - the federal response to California's medical-marijuana law. New Engl J Med. 1997;337(6):435-439. (Pubitemid 27328383)
3. Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med. 2010;362(16):1453-1457.
4. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2(5):291-298. (Pubitemid 38368569)
5. Voth EA. Guidelines for prescribing medical marijuana. West J Med. 2001;175(5):305-306. (Pubitemid 33054629)
6. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(suppl 1):S163-S171. (Pubitemid 43077274)
7. DuPont RL. The Selfish Brain: Learning from Addiction. Center City, MN: Hazelden; 2000.
8. Herer J. The Emperor Wears No Clothes. http://www.electricemperor.com/ eecdrom/HTML/EMP/02/ECH02-03.HTM. Accessed September 12, 2011.
9. U.S. Constitution Online. Answers From the FAQ, Page 8: Q145. "What kind of paper was the Constitution written on?". http://www.usconstitution. net/constfaq-a8.html. Accessed September 12, 2011.
10. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5(3):153-168.
11. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1-25.
12. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153-157. (Pubitemid 44086488)
13. Fisar Z. Phytocannabinoids and endocannabinoids. Curr Drug Abuse Rev. 2009;2(1):51-75.
14. Turcotte D, Le Dorze JA, Esfahani F, Frost E, Gomori A, Namaka M. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother. 2010;11(1):17-31.
15. Cohen PJ. Medical marijuana 2010: it's time to fix the regulatory vacuum. J Law Med Ethics. 2010;38(3):654-666.
16. Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000;57(6):547-552. (Pubitemid 30349434)
17. Martin BR. Medical marijuana - moving beyond the smoke. Lancet. 2002;360(9326):4-5. (Pubitemid 34756484)
18. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord. 2005;4(5):507-530.
19. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999;83(4):637-649. (Pubitemid 29458833)
20. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383-1391.
21. Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5(6):341-357.
22. Di Forti M, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? Curr Opin Psychiatry. 2007;20(3):228-234. (Pubitemid 46588294)
23. Ben Amar M, Potvin S. Cannabis and psychosis: what is the link? J Psychoactive Drugs. 2007;39(2):131-142. (Pubitemid 47105695)
24. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry. 2001;178:107-115. (Pubitemid 32158072)
25. Robson P. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011;10(5):675-685.
26. O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J. 2007;4:16.
27. Wilkins MR. Cannabis and cannabis-based medicines: potential benefits and risks to health. Clin Med. 2006;6(1):16-18.
28. Kalant H. Smoked marijuana as medicine: not much future. Clin Pharmacol Ther. 2008;83(4):517-519. (Pubitemid 351417065)
29. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-246. (Pubitemid 41773895)
30. Gerra G, Zaimovic A, Gerra ML, et al. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov. 2010;5(1):46-52.
31. Burgdorf JR, Kilmer B, Pacula RL. Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend. 2011;117(1):59-61.
32. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24(7):515-523.
33. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30(3):271-280.
34. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? a qualitative systematic review. BMJ. 2001;323(7303):13-16. (Pubitemid 32681998)
35. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. J Pain Palliat Care Pharmacother. 2009;23(1):4-25.
36. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669-1678. (Pubitemid 351899653)
37. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS. 2004;18(4):215-228. (Pubitemid 38558998)
38. Ogborne AC, Smart RG, Weber T, Birchmore-Timney C. Who is using cannabis as a medicine and why: an exploratory study. J Psychoactive Drugs. 2000;32(4):435-443. (Pubitemid 32104614)
39. Raphael B, Wooding S, Stevens G, Connor J. Comorbidity: cannabis and complexity. J Psychiatr Pract. 2005;11(3):161-176. (Pubitemid 40756755)
40. Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J. 2009;6:35-39.
41. Marmor JB. Medical marijuana. West J Med. 1998;168(6):540-543.
42. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J. 2007;4:11.
43. Van Dam NT, Earleywine M. Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy. 2010;21(6):511-513.
44. Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry. 2007;20(4):393-397. (Pubitemid 46889667)
45. Nierengarten MB. Guidelines needed for medical use of marijuana. Lancet Oncol. 2007;8(11):965.
46. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005;59(3):291-295. (Pubitemid 40352745)
47. Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43(2):128-135.
48. Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178:116-122. (Pubitemid 32158073)
49. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479-488. (Pubitemid 34260997)
50. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195- 1198. (Pubitemid 35398781)
51. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007;9(4):413-430. (Pubitemid 351187565)
52. Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry. 2009;21(2):104-112.
53. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction. 2000;95(11):1621-1630.
54. Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry. 2010;11(2, pt 2):208-219.
55. Schubart CD, Boks MP, Breetvelt EJ, et al. Association between cannabis and psychiatric hospitalization. Acta Psychiatr Scand. 2011;123(5):368-375.
56. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007;8(11):885-895. (Pubitemid 350006219)
57. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10(8):1665-1669. (Pubitemid 29354290)
58. Malone DT, Hill MN, Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol. 2010;160(3):511-522.
59. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-328. (Pubitemid 47094993)
60. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.
61. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 2003;71(1):37-48. (Pubitemid 36734857)
62. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319-327. (Pubitemid 34857999)
63. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273-279. (Pubitemid 24127299)
64. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167(8):987-993.
65. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31(3):608-612. (Pubitemid 41253312)
66. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers. 2007;4(8):1744-1769.
67. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008;13(2):253-263. (Pubitemid 351692985)
68. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol. 2010;92(3):370-385.
69. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-1127. (Pubitemid 40615773)
70. Jacobus J, Bava S, Cohen-Zion M, Mahmood O, Tapert SF. Functional consequences of marijuana use in adolescents. Pharmacol Biochem Behav. 2009;92(4):559-565.
71. Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738.
72. Kokkevi A, Nic Gabhainn S, Spyropoulou M. Early initiation of cannabis use: a cross-national European perspective. J Adolesc Health. 2006;39(5):712-719. (Pubitemid 44529027)
73. Hall W, Lynskey M. The challenges in developing a rational cannabis policy. Curr Opin Psychiatry. 2009;22(3):258-262.
74. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 2006;101(4):556-569. (Pubitemid 43375619)
75. Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M. Reverse gateways? frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction. 2005;100(10):1518-1525. (Pubitemid 41442321)
76. Luzi S, Morrison PD, Powell J, di Forti M, Murray RM. What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox Res. 2008;14(2-3):105-112.
77. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555-561.
78. Bottorff JL, Johnson JL, Moffat BM, Mulvogue T. Relief-oriented use of marijuana by teens. Subst Abuse Treat Prev Policy. 2009;4:7.
79. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two. J Pain Palliat Care Pharmacother. 2009;23(2):120-140.
80. Kahan M, Srivastava A. Is there a role for marijuana in medical practice? no. Can Fam Physician. 2007;53(1):22-25.
81. Ware MA. Is there a role for marijuana in medical practice? yes. Can Fam Physician. 2007;53(1):22-25.
82. Schwartz RH, Voth EA. Marijuana as medicine: making a silk purse out of a sow's ear. J Addict Dis. 1995;14(1):15-21.
83. MacDonald J. Medical marijuana: informational resources for family physicians. Am Fam Physician. 2009;80(8):779.
84. Marx J. Drug development; drugs inspired by a drug. Science. 2006;311(5759):322-325.
85. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101-106. (Pubitemid 32158071)
86. Di Marzo V, Petrocellis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med. 2006;57:553-574. (Pubitemid 43262007)
87. Carter GT, Ugalde V. Medical marijuana: emerging applications for the management of neurologic disorders. Phys Med Rehabil Clin N Am. 2004;15(4):943-954, ix. (Pubitemid 39349072)
88. Iversen L. Cannabis and the brain. Brain. 2003;126(pt 6):1252-1270. (Pubitemid 36644373)
89. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126(1):21-38.
90. Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry. 2009;21(2):113-121.
91. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009;23(5):597-602.
92. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov. 2008;7(5):438-455. (Pubitemid 351649182)
93. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57(8):1140-1155.
94. Oesch S, Gertsch J. Cannabinoid receptor ligands as potential anticancer agents - high hopes for new therapies? J Pharm Pharmacol. 2009;61(7):839-853.
95. Di Marzo V, Piscitelli F. Gut feelings about the endocannabinoid system. Neurogastroenterol Motil. 2011;23(5):391-398.
96. Parolaro D, Realini N, Vigano D, Guidali C, Rubino T. The endocannabinoid system and psychiatric disorders. Exp Neurol. 2010;224(1):3-14.
97. Medical marijuana. Med Lett Drugs Ther. 2010;52(1330):5-6.
98. Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol. 2004;143(2):227-234. (Pubitemid 39315142)
99. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction. 2010;105(3):494-503.
100. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(5):849-863. (Pubitemid 39195275)
101. Perez J, Ribera MV. Managing neuropathic pain with Sativex: a review of its pros and cons. Expert Opin Pharmacother. 2008;9(7):1189-1195. (Pubitemid 351721755)
102. Musto DF. The Marihuana Tax Act of 1937. Arch Gen Psychiatry. 1972;26(2):101-108.
103. Harris G. Researchers find study of medical marijuana discouraged. New York Times. 2010. Available at: http://www.nytimes.com/2010/01/19/health/policy/ 19marijuana.html?scp=1&sq= Researchers%20find%20study%20of%20medical%20marijuana%20discouraged&st=cse. Accessed January 5, 2011.
104. Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006;81(1):77-84. (Pubitemid 43054321)
105. Gostin LO. Medical marijuana, American federalism, and the Supreme Court. JAMA. 2005;294(7):842-844. (Pubitemid 41175728)
106. Duara N. 4 Americans get pot from US government. 2011. http://www.13abc.com/story/15565279/4-americans-get-pot-from-us-government? clientty. Accessed October 8, 2011.
107. Seamon MJ. The legal status of medical marijuana. Ann Pharmacother. 2006;40(12):2211-2215. (Pubitemid 44954442)
108. Medical Marijuana - ProCon.org: 16 Legal medical Marijuana States and DC: Laws, Fees, and Possession Limits. 2011. http://medicalmarijuana.procon.org/ view.resource.php?resourceID=000881. Accessed August 20, 2011.
109. Chen K, Kandel DB. Predictors of cessation of marijuana use: an event history analysis. Drug Alcohol Depend. 1998;50(2):109-121. (Pubitemid 28276182)
110. Duncan GJ, Wilkerson B, England P. Cleaning up their act: the effects of marriage and cohabitation on licit and illicit drug use. Demography. 2006;43(4):691-710. (Pubitemid 44914499)
111. Dresser R. Irrational basis: the legal status of medical marijuana. Hastings Cent Rep. 2009;39(6):7-8.
112. Steinbrook R. Medical marijuana, physician-assisted suicide, and the Controlled Substances Act. N Engl J Med. 2004;351(14):1380-1383. (Pubitemid 39288161)